In addition to these, 98 miRNAs were expressed in both the metastasis and the corresponding primary tumor xenograft passages, 22 miRNAs were exclusively expressed in metastatic xenograft passages, 12 miRNAs were exclusive to xenografts from primary tumor, and 11 miRNAs were expressed
as well in controls as in primary tumor xenograft passages. selleck inhibitor Table 4 The 46 miRNAs detected in all xenografts samples, while absent from all control samples. miRNA miRNA miRNA miRNA hsa-miR-1224-5p hsa-miR-451 hsa-miR-188-5p hsa-miR-629* hsa-miR-126* hsa-miR-483-5p hsa-miR-652 Sotrastaurin supplier hsa-miR-663 hsa-miR-1290 hsa-miR-486-5p hsa-miR-19b-1* hsa-miR-7-1* hsa-miR-1300 hsa-miR-194 hsa-miR-215 hsa-miR-744 hsa-miR-135a* hsa-miR-195* hsa-miR-219-5p hsa-miR-877* hsa-miR-142-3p
hsa-miR-501-3p hsa-miR-873 hsa-miR-9 hsa-miR-144 hsa-miR-502-3p hsa-miR-30c-1* hsa-miR-9* hsa-miR-150 hsa-miR-505* hsa-miR-328 hsa-miR-150* hsa-miR-223 hsa-miR-338-3p hsa-miR-181c* hsa-miR-564 hsa-miR-371-5p hsa-miR-548c-5p hsa-miR-421 hsa-miR-345 hsa-miR-557 hsa-miR-339-3p hsa-miR-378 hsa-miR-33a hsa-miR-598 hsa-miR-629 Eleven miRNAs were expressed in both control samples and primary tumor xenograft passages but not at all in metastatic samples (Table 5, Figure 3). Nine of these (miR-214*, miR-154*, miR-337-3P, miR-369-5p, miR-409-5p, miR-411, miR-485-3p, miR-487a, miR-770-5p) were also preferentially expressed in other primary tumor xenografts when compared to metastatic xenograft passages. Table 5 MiRNAs expressed in xenograft passages of A) Case 430 primary tumor while absent in lung metastasis, 12 miRNAs, B) Case 430 lung metastasis while absent in primary tumor, 18 miRNAs and C) medroxyprogesterone Case 430 primary tumors and control, while absent in lung metastasis, 11 miRNAs miRNAs expressed in A) Xenograft passages from Primary tumor (12 miRNAs) B) Xenograft passages
from lung metastasis (18 miRNAs) C) Control and xenograft passages from Primary tumor (11 miRNAs) hsa-miR-1237 hsa-miR-1183 hsa-miR-595 hsa-miR-154* hsa-miR-139-3p hsa-miR-124 hsa-miR-601 hsa-miR-214* hsa-miR-139-5p hsa-miR-1471 hsa-miR-623 hsa-miR-337-3p hsa-miR-202 hsa-miR-32* hsa-miR-662 hsa-miR-34a* hsa-miR-30b* hsa-miR-424* hsa-miR-664* hsa-miR-369-5p hsa-miR-450a hsa-miR-486-3p hsa-miR-671-5p hsa-miR-409-5p hsa-miR-490-3p hsa-miR-520b hsa-miR-411 hsa-miR-501-5p hsa-miR-520e hsa-miR-485-3p hsa-miR-502-5p hsa-miR-96 hsa-miR-487a hsa-miR-548 d-5p hsa-miR-877 hsa-miR-542-3p hsa-miR-602 hsa-miR-95 hsa-miR-770-5p hsa-miR-885-5p TSA HDAC hsa-miR-765 Figure 3 Hierarchical clustering of the xenograft passages. Note that the xenograft passages show a distinct expression profile that separates them from the mesenchymal stem cell control samples.